Personalis

Personalis EBIT Margin

The EBIT Margin (Operating Margin) of Personalis (PSNL) as of Oct 11, 2026 is -126.43 %. In the previous year, EBIT Margin (Operating Margin) was -80.68 % — a change of 56.71% (lower).

EBIT Margin

-126.43 %

YoY

56.71%

Last updated:

EBIT Margin (Operating Margin) of Personalis is 2025 -126.43 % . EBIT Margin (Operating Margin) of Personalis was 2024 -80.68 % . It decreases by 56.71% lower compared to the previous year.

For Personalis, the operating (EBIT) margin of -126.8% is down versus -76.6% a few years ago.

The Personalis EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-47.61 USD
Jan 1, 2019
-34.38 USD
Jan 1, 2020
-53.59 USD
Jan 1, 2021
-76.44 USD
Jan 1, 2022
-177.61 USD
Jan 1, 2023
-131.05 USD
Jan 1, 2024
-80.68 USD
Jan 1, 2025
-126.43 USD
The Personalis EBIT Margin history
YEAREBIT MarginYoY
-126.43 %+56.71%
-80.68 %-38.43%
-131.05 %-26.22%
-177.61 %+132.35%
-76.44 %+42.65%
-53.59 %+55.87%
-34.38 %-27.79%
-47.61 %-80.03%
-238.37 %—
Access this data via the Eulerpool API

Personalis Stock analysis

What does Personalis do? Personalis Inc is a diagnostic company specializing in the development of tests for personalized medicine. The company was founded in 2011 by Dr. Richard Chen and Dr. Erin Newburn and is headquartered in Menlo Park, California. They initially focused on developing genomic tools for cancer diagnosis and treatment but have expanded their offerings to include tests for rare genetic diseases, immunotherapies, and precision oncology drugs. They work closely with pharmaceutical and biotechnology companies as well as academics to develop innovative therapeutic approaches. Their business model is based on making genomics biology usable for personalized medicine and clinical research. They have a wide portfolio of genomic-based solutions for personalized medicine, including tests for tumor mutations, tumor-specific neoantigens, rare genetic diseases, and personalized immunotherapy. They also offer customized genomic solutions for pharmaceutical and biotechnology companies. Personalis Inc aims to establish personalized medicine quickly and effectively to provide the best possible outcome for patients. Personalis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Personalis stock

EBIT Margin (Operating Margin) of Personalis is -126.43 % in 2025.

EBIT Margin (Operating Margin) of Personalis changed from -80.68 % to -126.43 %, representing a 56.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Personalis since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Personalis with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

Margins — Personalis

All Key Metrics — Personalis